Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

data-sets have been transferred and the authorities have confirmed the receipt and navigability of the information. Both the rolling NDA and the electronic format could greatly facilitate the review process.

The first modules of the NDA package are ready and will be filed before year-end 2007. The remaining modules are expected to be transferred and filing is forecast to be completed by the end of February 2008.

Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "We are pleased with the progress made across the several different programmes.

Firstly, initiation of patient enrolment in the Phase II trial with intravenous iclaprim in HAP/VAP/HCAP provides a good basis for the completion of the trial within the planned timelines. HAP/VAP/HCAP is a serious, life-threatening condition with a high medical need. We believe that iclaprim could have a high potential in this indication based on its potent and bactericidal action on MRSA and its good distribution in those lung compartments where the key respiratory pathogens reside."

Dr Islam added: "Moreover, we are very pleased with the results of the ascending dose trial with oral iclaprim, which show a good tolerability at high doses. We are now working to complete the Phase I programme while at the same time discussing with the regulatory authorities regarding the potential next steps in the development path of oral iclaprim.

Work on the NDA for intravenous iclaprim in cSSSI is progressing well. We expect to file the first modules of the package before year-end and complete the filing by the end of February 2008. After finalising the NDA filing, our next steps will focus on the preparation of the commercial launch of iclaprim."

Conference Call

Arpida will host a conference call to discuss these recent developments, today, 11 December 2007, at 3 pm CET. The dial-in numbers are:

+41-(0)91-610-56-00 (Europe)

+44-(0)207-107-06-11 (UK)

+1-(1)866-29
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2
... WOODCLIFF LAKE, N.J., Dec. 27 - Eisai Co.,Ltd. ... Eisai Inc.,(Headquarters: New Jersey, Chairman and CEO: Hajime ... against Mutual Pharmaceutical Co.,Inc. and United Research Laboratories, ... abbreviated new drug application (ANDA),to the U.S. Food ...
... Resigns as President and CEO -, DALLAS, Dec. ... today that current Chairman Jeffrey B.,Davis has been appointed ... resigned as President and CEO of the Company for ... of Directors., "I believe that Access has an ...
... ROCK, Colo., Dec. 24 AspenBio Pharma,Inc. (Nasdaq: ... of novel drugs and diagnostics for animals and humans, ... of existing and,new investors. $18.2 million in gross proceeds ... of the company,s common stock., Net proceeds to ...
Cached Biology Technology:U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing 2U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing 3Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 2Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 3AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock 2AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock 3
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... papers that have been recently published in Geophysical Research ... Earth ( JGR-B ) and Journal of Geophysical ... 1. An earthquake in Japan caused large waves in Norwegian ... in Ohio, 3. The Arctic is especially sensitive to black ...
... Johns Hopkins have uncovered a protein switch that can ... depending on the signals it detects. Its dual role ... network of signals that shapes our brain,s circuitry, the ... the July 31 issue of the Journal of ...
... A strain of bacteria that causes skin and soft tissue ... study to be published in mBio , the online ... who conducted the genetic analysis of strains of Staphylococcus ... to methicillin after they crossed over into humans around forty ...
Cached Biology News:AGU journal highlights -- Aug. 13, 2013 2AGU journal highlights -- Aug. 13, 2013 3AGU journal highlights -- Aug. 13, 2013 4AGU journal highlights -- Aug. 13, 2013 5AGU journal highlights -- Aug. 13, 2013 6AGU journal highlights -- Aug. 13, 2013 7AGU journal highlights -- Aug. 13, 2013 8Newly discovered 'switch' plays dual role in memory formation 2MRSA strain in humans originally came from cattle 2MRSA strain in humans originally came from cattle 3
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: